Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.

ABSTRACT:

Background

Recent genomic and bioinformatic technological advances have made it possible to dissect the immune response to personalized neoantigens encoded by tumor-specific mutations. However, timely and efficient identification of neoantigens is still one of the major obstacles to using personalized neoantigen-based cancer immunotherapy.

Methods

Two different pipelines of neoantigens identification were established in this study: (1) Clinical grade targeted sequencing was performed in patients with refractory solid tumor, and mutant peptides with high variant allele frequency and predicted high HLA-binding affinity were de novo synthesized. (2) An inventory-shared neoantigen peptide library of common solid tumors was constructed, and patients' hotspot mutations were matche

SUBMITTER: Chen F 

PROVIDER: S-EPMC6486339 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature